Integrum AB (FRA:6Y1) ROCE %: -44.60% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Y1 Integrum AB FRA:6Y1
57 GF Score
Price €0.69
GF Value €1.54
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Integrum AB ROCE %?

Integrum AB FRA:6Y1 -2.13% 57 ROCE % is -44.60% as of Apr. 2026. GuruFocus rates FRA:6Y1 with a GF Score™ of 57/100 and a GF Value™ of €1.54 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Integrum AB's annualized ROCE % for the quarter that ended in Apr. 2026 was -44.60%.

Integrum AB  (FRA:6Y1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Integrum AB ROCE % Related Terms

Integrum AB ROCE % Historical Data

* Premium members only.

The historical data trend for Integrum AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrum AB ROCE % Chart

Integrum AB Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.29 -13.22 4.38 -26.24 -30.16

Integrum AB Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.47 -27.93 -27.22 -22.31 -44.60
FRA:6Y1
57GF Score
Integrum AB FRA:6Y1
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integrum AB ROCE % Calculation

Integrum AB's annualized ROCE % for the fiscal year that ended in Apr. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2026 )  (A: Apr. 2025 )(A: Apr. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2026 )  (A: Apr. 2025 )(A: Apr. 2026 )
=-4.897/( ( (18.501 - 2.025) + (18.781 - 2.785) )/ 2 )
=-4.897/( (16.476+15.996)/ 2 )
=-4.897/16.236
=-30.16 %

Integrum AB's ROCE % of for the quarter that ended in Apr. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=-7.416/( ( (19.302 - 2.041) + (18.781 - 2.785) )/ 2 )
=-7.416/( ( 17.261 + 15.996 )/ 2 )
=-7.416/16.6285
=-44.60 %

(1) Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -44.60% mean?
Integrum AB (FRA:6Y1) has a ROCE % of -44.60% as of Apr. 2026.
Is Integrum AB's ROCE % too high?
Integrum AB's current ROCE % is -44.60%. Overall, Integrum AB has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrum AB's ROCE % compare to ABT and SYK?
Integrum AB's ROCE % of -44.60% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.22, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrum AB's current ROCE % is -44.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrum AB stock overvalued right now?
Based on GuruFocus' analysis, Integrum AB (FRA:6Y1) is currently considered Possible Value Trap. The stock's GF Value™ is €1.54, compared to a current price of €0.69 — trading 55.3% below its estimated fair value. The current ROCE % is -44.60%. Integrum AB's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Integrum AB (FRA:6Y1), the current ROCE % is -44.60% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrum AB (FRA:6Y1) Overvalued in 2026?

Based on GuruFocus' analysis, Integrum AB stock appears to be undervalued. The current stock price of €0.69 is trading 55.3% below its estimated GF Value™ of €1.54. GuruFocus considers Integrum AB to be Possible Value Trap.

Key valuation signals for FRA:6Y1:

  • ROCE %: -44.60%
  • GF Value™: €1.54 vs. price of €0.69 (55.3% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:6Y1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integrum AB Business Description

Other Exchanges INTEG B:Sweden
Address Krokslatts Fabriker 50, Molndal, SWE, SE-431 37
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.
57GF Score

Get the complete analysis for FRA:6Y1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€1.54
GF Value